BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

MacuSight, Inc. Appoints Brian C. Cunningham To Board Of Directors


11/2/2006 11:12:49 AM

UNION CITY, Calif., Nov. 2 /PRNewswire/ -- MacuSight(TM), Inc., a developer of innovative therapeutics for the treatment of severe ocular diseases and conditions, today announced the appointment of Brian C. Cunningham to its board of directors. Mr. Cunningham presently serves as chief executive officer of DaoGen, Inc. and Clerigen, Inc., both early stage biopharmaceutical companies, and is Of Counsel to Cooley Godward Kronish LLP in its business department. In addition, Mr. Cunningham is a director of Synarc, Inc., a private, imaging-based clinical research organization.

"What makes Brian such a great fit for MacuSight is his impressive breadth of expertise which spans nearly every aspect of the biotechnology and biopharmaceutical industries. With his depth of experience in the life sciences -- from legal practice to operations -- Brian will serve as a critical resource for MacuSight as we continue to grow as a company," said David A. Weber, Ph.D., MacuSight's president and chief executive officer. "We are excited to have someone of his caliber join our board and look forward to the direction and insight that he will provide to the company moving forward."

In 2003, Mr. Cunningham rejoined Cooley Godward Kronish LLP, having previously served as a partner and the head of the firm's life sciences practice from 1989-1998. During the time between his tenures at Cooley Godward Kronish LLP, he held the positions of president and chief operating officer of Rigel Pharmaceuticals, Inc., where he played a critical role in strategically growing the company into a late-stage developer of innovative pharmaceutical products. His numerous contributions to Rigel Pharmaceuticals included providing key oversight for the company's successful initial public offering in 2000. From 1982-1988, he was a member of Genentech's senior management team during a period of rapid growth for the company. Serving as Genentech's vice president, secretary and general counsel, Mr. Cunningham was responsible for completing a number of significant corporate partnering transactions with major pharmaceutical companies around the world, as well as overseeing numerous innovative financial transactions.

Previously, Mr. Cunningham has served as adjunct professor in biotechnology law at Santa Clara University Law School and as a member of the boards of QuestCor, Inc., SAMCEDA, the Bay Area Bioscience Center and Partners In School Innovation. He is a member of the bar in California, New York and Missouri, and a member of the American Law Institute.

"I am very excited to join the MacuSight team and have the opportunity to support and contribute to the growth of this emerging pharmaceutical company," stated Mr. Cunningham. "With the broad therapeutic potential of sirolimus, MacuSight's lead product candidate, and the proven track record of the company's management team, MacuSight is strongly positioned to play a critical role in advancing the treatment of severe ocular diseases and conditions."

About MacuSight

MacuSight is a privately-held pharmaceutical company focused on developing innovative therapeutics for the treatment of severe ocular diseases and conditions. The company is dedicated to preserving patients' vision by identifying known, highly-potent and broad-acting small molecule drug compounds that may possess efficacy in treating and/or preventing diseases or conditions of the eye. As part of its unique product development philosophy, MacuSight also concentrates on the optimal delivery of these compounds into the eye. By combining its compounds with innovative delivery approaches, the company strives to optimize the efficacy, safety, convenience and cost- effectiveness of its product candidates.

The company's lead development program is centered on advancing sirolimus (rapamycin) as a potential next-generation therapeutic for the treatment and prevention of wet age-related macular degeneration (wet AMD) and the treatment of diabetic macular edema (DME), a manifestation of diabetic retinopathy.

MacuSight, Inc.

CONTACT: investors, Stephanie Diaz, +1-415-675-7400, orsdiaz@vidacommunication.com, or media, Tim Brons, +1-415-675-7402, ortbrons@vidacommunication.com, both of Vida Communication, for MacuSight



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES